Vanguard Group Inc Tricida, Inc. Transaction History

Vanguard Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$0.14 - $12.49 $116,749 - $10.4 Million	833,926 Added 50.18%	2,495,786 $374,000
Q3 2022 Nov 14, 2022	BUY	$8.51 - $13.6 $498,515 - $796,688	58,580 Added 3.65%	1,661,860 $17.4 Million
Q2 2022 Aug 12, 2022	BUY	$7.31 - $11.85 $1.26 Million - $2.04 Million	172,167 Added 12.03%	1,603,280 $15.5 Million
Q1 2022 May 13, 2022	BUY	$7.35 - $10.63 $25,144 - $36,365	3,421 Added 0.24%	1,431,113 $11.8 Million
Q4 2021 Feb 14, 2022	BUY	$4.19 - $9.56 $492,454 - $1.12 Million	117,531 Added 8.97%	1,427,692 $13.6 Million
Q3 2021 Nov 12, 2021	BUY	$3.56 - $4.64 $7,906 - $10,305	2,221 Added 0.17%	1,310,161 $6.08 Million
Q2 2021 Aug 13, 2021	BUY	$3.95 - $5.41 $5.17 Million - $7.08 Million	1,307,940 New	1,307,940 $5.65 Million

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.